Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Huntington's Dementia Clear all
Completed No phase listed Observational

Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD

NCT00491842
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 3, 2026, 10:59 AM EDT
Not listed Phase 1 Interventional

Ursodiol in Huntington's Disease

NCT00514774
View directory record Official record
Conditions
Huntington Disease
Interventions
ursodiol, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Oct 3, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

NCT00712426
View directory record Official record
Conditions
Huntington's Disease
Interventions
Creatine Monohydrate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
38
States / cities
Birmingham, Alabama • Irvine, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 3, 2026, 10:59 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cooperative Huntington's Observational Research Trial

NCT00313495
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
HP Therapeutics Foundation
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 3, 2026, 10:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cognitive Assessment Battery (CAB) Beta Study

NCT01290861
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
CHDI Foundation, Inc.
Other
Eligibility
25 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

NCT05358717
View directory record Official record
Conditions
Huntington Disease
Interventions
PTC518, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
25 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
La Jolla, California • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Completed No phase listed Observational

Development of the Virtual Unified Huntington's Disease Rating Scale

NCT05748288
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
Huntington Study Group
Network
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 3, 2026, 10:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mitochondrial Biomarkers in Huntington's Disease

NCT04515550
View directory record Official record
Conditions
Huntington Disease
Interventions
lumbar puncture
Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
20 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

NCT03515213
View directory record Official record
Conditions
Huntington Disease
Interventions
Fenofibrate, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 3, 2026, 10:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease

NCT07451613
View directory record Official record
Conditions
Huntington Disease
Interventions
hNSC-01
Biological
Lead sponsor
Leslie Thompson
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of tDCS on Subcortical Brain Functioning

NCT01602276
View directory record Official record
Conditions
Brain Damage, Chronic
Interventions
Transcranial Direct Current Stimulation (tDCS)
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 3, 2026, 10:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

NCT07010705
View directory record Official record
Conditions
Huntington Disease, Healthy
Interventions
ActiGraph LEAP, Axivity AX6
Device
Lead sponsor
University of Rochester
Other
Eligibility
25 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1Phase 2 Interventional

Creatine Therapy for Huntington's Disease

NCT00026988
View directory record Official record
Conditions
Huntington's Disease
Interventions
Creatine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
Boston, Massachusetts • Long Island City, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 3, 2026, 10:59 AM EDT
Not listed Not applicable Interventional

Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study

NCT03724136
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia, Mixed, Parkinson-Dementia Syndrome, Chronic Traumatic Encephalopathy, Huntington's Dementia, Wernicke Korsakoff Syndrome, Traumatic Brain Injury, Dementia, Multi-Infarct, Autism, Autism Spectrum Disorder, Autistic Behavior, Autistic Disorder, Current or Active State, Cadasil, LATE Limbic-predominant Age-related TDP-43 Encephalopathy
Interventions
Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 3, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

NCT05655520
View directory record Official record
Conditions
Huntington's Disease
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 3, 2026, 10:59 AM EDT
Completed No phase listed Observational

HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States

NCT03628235
View directory record Official record
Conditions
Huntington's Disease
Interventions
Online survey
Behavioral
Lead sponsor
CHDI Foundation, Inc.
Other
Eligibility
21 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Englewood, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease

NCT01735981
View directory record Official record
Conditions
Huntington's Disease
Interventions
Video game exercise using Dance Dance Revolution, hand-held video game
Other
Lead sponsor
Anne Kloos
Other
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease

NCT04514367
View directory record Official record
Conditions
Huntington Disease
Interventions
ANX005
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Birmingham, Alabama • Englewood, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

NCT00825084
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

Treatment of Huntington's Chorea With Amantadine

NCT00001930
View directory record Official record
Conditions
Chorea, Huntington's Disease
Interventions
Amantadine
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

NCT05107128
View directory record Official record
Conditions
Huntington's Disease
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease

NCT01485965
View directory record Official record
Conditions
Huntington's Disease
Interventions
SEN0014196
Drug
Lead sponsor
Siena Biotech S.p.A.
Industry
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

NCT03854019
View directory record Official record
Conditions
Huntington Disease, Irritability
Interventions
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study

NCT06490367
View directory record Official record
Conditions
Huntington Disease
Interventions
Time-Restricted Eating Diet
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 3, 2026, 10:59 AM EDT